Terms: = Cervical cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
312 results:
1. pd-l1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.
Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.
Hosseini MS; Shafizadeh F; Bahremani MH; Farzaneh F; Ashrafganjoei T; Arab M; Talayeh M; Jafari F; Abdshah A
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2057. PubMed ID: 38662366
[TBL] [Abstract] [Full Text] [Related]
3. Adenosine increases pd-l1 expression in mesenchymal stromal cells derived from cervical cancer through its interaction with A
Marín-Aquino LA; Mora-García ML; Moreno-Lafont MC; García-Rocha R; Montesinos-Montesinos JJ; López-Santiago R; Sánchez-Torres LE; Torres-Pineda DB; Weiss-Steider B; Hernández-Montes J; Don-López CA; Monroy-García A
Cell Biochem Funct; 2024 Apr; 42(3):e4010. PubMed ID: 38613217
[TBL] [Abstract] [Full Text] [Related]
4. Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V; Virano E; Salutari V; Ricotti A; Pisano C; Ducceschi M; Turitto G; Scandurra G; Petrella MC; Forestieri V; Rizzetto M; Mammoliti S; Artioli G; Cioffi R; Borsotti L; Bellero M; Rognone C; Carbone V; Ferrandina G; Mantiero M; Azzolina C; Geninatti E; Pignata S; Valabrega G
Eur J Cancer; 2024 May; 203():114039. PubMed ID: 38598922
[TBL] [Abstract] [Full Text] [Related]
5. Associations of PD-1 and pd-l1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
6. Advanced detection of cervical cancer biomarkers using engineered filamentous phage nanofibers.
Zhou X; Wang Y; Bao M; Chu Y; Liu R; Chen Q; Lin Y
Appl Microbiol Biotechnol; 2024 Feb; 108(1):221. PubMed ID: 38372795
[TBL] [Abstract] [Full Text] [Related]
7. Evaluation of the anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6/E7 combined with cisplatin in a xenograft model of cervical cancer.
Kang SW; Kang OJ; Lee JY; Kim H; Jung H; Kim H; Lee SW; Kim YM; Choi EK
PLoS One; 2024; 19(2):e0298815. PubMed ID: 38363779
[TBL] [Abstract] [Full Text] [Related]
8. Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.
Wang YZ; Wang JS; Du J; Tang XL; Xiao JP
Front Immunol; 2024; 15():1305810. PubMed ID: 38327524
[TBL] [Abstract] [Full Text] [Related]
9. Clinical significance of integrin αV and β superfamily members and focal adhesion kinase activity in oral squamous cell carcinoma: a retrospective observational study.
Sakurai S; Ishida Y; Shintani T; Yamasaki S; Matsui K; Hamana T; Nobumoto T; Yanamoto S; Hayashido Y
Pathol Oncol Res; 2024; 30():1611571. PubMed ID: 38312516
[No Abstract] [Full Text] [Related]
10. Prevalence of pd-l1 in cervical cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
[TBL] [Abstract] [Full Text] [Related]
11. Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCTs): A Scoping Review of 511 Cases, Including 2 New Cases.
Watrowski R; Palumbo M; Guerra S; Gallo A; Zizolfi B; Giampaolino P; Bifulco G; Di Spiezio Sardo A; De Angelis MC
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38276058
[TBL] [Abstract] [Full Text] [Related]
12. Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.
Lin YT; Wang C; He XY; Yao QM; Chen J
Front Immunol; 2023; 14():1345942. PubMed ID: 38274823
[TBL] [Abstract] [Full Text] [Related]
13. Knowledge mapping of immunotherapy in cervical carcinoma: a bibliometric analysis (2000-2023).
Song L; Liang X; Zhu M; Su Q; Li F
Front Immunol; 2023; 14():1328103. PubMed ID: 38264659
[TBL] [Abstract] [Full Text] [Related]
14. HPV16
Konstantopoulos G; Leventakou D; Saltiel DR; Zervoudi E; Logotheti E; Pettas S; Karagianni K; Daiou A; Hatzistergos KE; Dafou D; Arsenakis M; Kottaridi C
Viruses; 2024 Jan; 16(1):. PubMed ID: 38257813
[TBL] [Abstract] [Full Text] [Related]
15. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.
Passarelli A; Pisano C; Coppola E; Ventriglia J; Cecere SC; Di Napoli M; Carideo L; Lastoria S; Pignata S
Front Immunol; 2023; 14():1303893. PubMed ID: 38193091
[TBL] [Abstract] [Full Text] [Related]
16. An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for cervical cancer.
Lukovic J; Pintilie M; Han K; Fyles AW; Bruce JP; Quevedo R; Pugh TJ; Fjeldbo CS; Lyng H; Milosevic MF
Clin Cancer Res; 2024 Mar; 30(6):1200-1207. PubMed ID: 38180733
[TBL] [Abstract] [Full Text] [Related]
17. cervical lymphoepithelioma-like carcinoma with deficient mismatch repair and loss of SMARCA4/BRG1: a case report and five related cases.
Miyama Y; Kato T; Sato M; Yabuno A; Hasegawa K; Yasuda M
Diagn Pathol; 2024 Jan; 19(1):6. PubMed ID: 38178127
[TBL] [Abstract] [Full Text] [Related]
18. Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic cervical cancer.
Oaknin A; Ghamande SA; Kasamatsu Y; Gil-Martin M; Grau-Bejar JF; Garcia-Duran C; Sato M; Siddiqui A; Chaudhary SP; Vugmeyster Y; Hasegawa K
Clin Cancer Res; 2024 Mar; 30(5):975-983. PubMed ID: 38165683
[TBL] [Abstract] [Full Text] [Related]
19. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
[TBL] [Abstract] [Full Text] [Related]
20. Systematic assessment of tumor necrosis at baseline in cervical cancer - An independent factor associated with poor outcome.
Chouchane-Mlik O; Oniga A; Latouche A; Halladjian M; Kleine-Borgmann FB; Gérardy JJ; Mittelbronn M; Kamal M; Scholl SM
Hum Pathol; 2024 Jan; 143():62-70. PubMed ID: 38135059
[TBL] [Abstract] [Full Text] [Related]
[Next]
